Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Pre Market Stock News Brief
Dec 01, 2008 10:05 AM
- Bookkeeping: Beginning Amylin Pharmaceuticals (AMLN)
Aug 20, 2008 01:26 PM
- Analyst Comments: Teekay, Advanced Micro, JC Penney, Zumiez, MarkWest Energy, UBS AG, Alkermes, Ev3 Inc
Aug 14, 2008 03:00 PM
- Few Thoughts and a Look at the Earnings in the Coming Week
Jul 28, 2008 01:20 AM
- Alkermes: Buyback Boosts Biotech Bet
Jun 30, 2008 09:52 AM
- Biotech Exhibiting a Quiet Strength
Jun 25, 2008 10:14 PM
- Analyst Comments: Tower Group, Schering-Plough, Ness Tech, Alkermes, Banco Bradesco, Anadigics, U.S. Bancorp
Jun 18, 2008 01:55 PM
- Searching For Positive Catalysts
Jun 16, 2008 09:57 AM
- Stay Confident About Biotech
Jun 12, 2008 01:20 AM
- UPDATE: Amylin Slides On Byetta Competition Concerns
Jun 09, 2008 02:33 PM
- Alkermes Regains Full Commercialization Rights to VIVITROL® in US
Dec 01, 2008 08:10 AM
- Alkermes’ Corporate Presentation to be Webcast at JPMorgan SMid Cap Conference
Nov 25, 2008 04:02 PM
- Alkermes’ Corporate Presentation to be Webcast at the NASDAQ Investor Program
Nov 24, 2008 04:02 PM
- Alkermes Presents Positive Preclinical Data on Novel, Proprietary
Molecule Designed to Improve Outcomes for Patients Taking Opioid
Analgesics
Nov 17, 2008 08:59 AM
- Alkermes' Corporate Presentation to be Webcast at Lazard Capital Markets Fifth Annual Healthcare Conference
Nov 11, 2008 04:02 PM
- Alkermes Announces Second Quarter Fiscal 2009 Results
Nov 06, 2008 04:07 PM
- Zacks Analyst Blog Highlights: Alkermes, Inc., Eli Lilly & Co., The Ryland Group, Epicor Software Corp. And Synopsys Inc.
Nov 03, 2008 01:13 AM
- Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2009
Oct 30, 2008 04:03 PM
- FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
Oct 09, 2008 04:23 PM
- David Anstice Elected to Alkermes' Board of Directors
Oct 08, 2008 08:33 AM
- Form 4 ALKERMES INC For: Nov 19 Filed by: Pugh Gordon G (10K)
Nov 20, 2008 05:00 PM
- Form 4 ALKERMES INC For: Nov 19 Filed by: LANDINE MICHAEL J (10K)
Nov 20, 2008 04:47 PM
- Form 4 ALKERMES INC For: Nov 19 Filed by: FRATES JAMES M (10K)
Nov 20, 2008 04:42 PM
- Form 4 ALKERMES INC For: Nov 19 Filed by: Ehrich Elliot (10K)
Nov 20, 2008 03:16 PM
- Form 4 ALKERMES INC For: Nov 19 Filed by: BROECKER DAVID A (10K)
Nov 20, 2008 03:01 PM
- Form 4 ALKERMES INC For: Nov 19 Filed by: BIBERSTEIN KATHRYN L (10K)
Nov 20, 2008 02:45 PM
- Form 4 ALKERMES INC For: Nov 17 Filed by: FRATES JAMES M (10K)
Nov 18, 2008 01:45 PM
- Form 4 ALKERMES INC For: Nov 05 Filed by: LANDINE MICHAEL J (10K)
Nov 07, 2008 12:32 PM
- Form 4 ALKERMES INC For: Nov 05 Filed by: Pugh Gordon G (10K)
Nov 06, 2008 06:30 PM
- Form 4 ALKERMES INC For: Nov 05 Filed by: POPS RICHARD F (10K)
Nov 06, 2008 06:23 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
ALKS
|
Compare to S&P
|
| YTD |
-52.66 %
|
-22.44 %
|
| 4 Weeks |
-25.30 %
|
-19.26 %
|
| 12 Weeks |
-45.05 %
|
-23.83 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -93.55 %
|
|
EPS Growth in Last Year: -71.43 %
|
|
Sales Growth in Last Quarter: -40.86 %
|
|
Sales Growth in Last Quarter: -19.26 %
|
|
|
